141![Joint Meeting of the Advisory Committee for Reproductive Health Drugs and the Drug Safety and Risk Management Advisory Committee December 9, 2011 Scott Monroe, MD Joint Meeting of the Advisory Committee for Reproductive Health Drugs and the Drug Safety and Risk Management Advisory Committee December 9, 2011 Scott Monroe, MD](https://www.pdfsearch.io/img/b8b34b1deea0852bd889d106f7c17f22.jpg) | Add to Reading ListSource URL: www.fda.govLanguage: English |
---|
142![Overactive bladder drugs compared - Consumer Reports Health Overactive bladder drugs compared - Consumer Reports Health](https://www.pdfsearch.io/img/d643f77aadcd6b7ff2079c7c187308ae.jpg) | Add to Reading ListSource URL: consumerhealthchoices.orgLanguage: English - Date: 2013-07-06 14:29:13
|
---|
143![NDA[removed]DITROPAN (oxybutynin chloride) Tablets (Final Draft submitted[removed]) NDA[removed]DITROPAN (oxybutynin chloride) Syrup (Final Draft submitted[removed]DITROPAN® (oxybutynin chloride) Tablets and Syru NDA[removed]DITROPAN (oxybutynin chloride) Tablets (Final Draft submitted[removed]) NDA[removed]DITROPAN (oxybutynin chloride) Syrup (Final Draft submitted[removed]DITROPAN® (oxybutynin chloride) Tablets and Syru](https://www.pdfsearch.io/img/9230378c54f4bf63e414ebf08d7330b3.jpg) | Add to Reading ListSource URL: www.fda.govLanguage: English - Date: 2007-04-09 09:20:37
|
---|
144![NDA[removed]S-013 Page 3 DITROPAN XL (oxybutynin chloride) Extended Release Tablets NDA[removed]S-013 Page 3 DITROPAN XL (oxybutynin chloride) Extended Release Tablets](https://www.pdfsearch.io/img/adac76496d6446a23d25d8a37bbec62f.jpg) | Add to Reading ListSource URL: www.fda.govLanguage: English - Date: 2007-04-09 09:20:38
|
---|
145![Pediatric Focused Safety Review: Beyaz (ethinyl estradiol, drospirenone, levomefolate calcium) Pediatric Advisory Committee Meeting September 11, 2012 Pediatric Focused Safety Review: Beyaz (ethinyl estradiol, drospirenone, levomefolate calcium) Pediatric Advisory Committee Meeting September 11, 2012](https://www.pdfsearch.io/img/f861ae859c35c7281a34194536d5af87.jpg) | Add to Reading ListSource URL: www.fda.govLanguage: English |
---|
146![FOOD AND DRUG ADMINISTRATION Center for Drug Evaluation and Research Meeting of the Peripheral and Central Nervous System Drugs Advisory Committee FDA White Oak Campus, Building 31, The Great Room (Rm[removed]White Oak Co FOOD AND DRUG ADMINISTRATION Center for Drug Evaluation and Research Meeting of the Peripheral and Central Nervous System Drugs Advisory Committee FDA White Oak Campus, Building 31, The Great Room (Rm[removed]White Oak Co](https://www.pdfsearch.io/img/33162c4cd432fe08c5ec1972c892cfa7.jpg) | Add to Reading ListSource URL: www.fda.govLanguage: English |
---|
147![Benchmark Positions, by Occupational Group AR Group BM Title K&S AR3a Benchmark Positions, by Occupational Group AR Group BM Title K&S AR3a](https://www.pdfsearch.io/img/d198a3ab1e7a20d7d5e1e33b7d47198d.jpg) | Add to Reading ListSource URL: www.psc.gov.yk.caLanguage: English - Date: 2014-09-12 18:38:23
|
---|
148![Microsoft Word[removed]4295b_01_02_Cover Memo_Murphy.doc Microsoft Word[removed]4295b_01_02_Cover Memo_Murphy.doc](https://www.pdfsearch.io/img/4607666cb2a50d7a36f32809abb4418f.jpg) | Add to Reading ListSource URL: www.fda.govLanguage: English - Date: 2007-04-09 09:20:36
|
---|
149![M I F E P R E X™ (Mifepristone) Tablets, 200 mg PRESCRIBER’S AGREEMENT We are pleased that you wish to become a provider of Mifeprex* (Mifepristone) Tablets, 200 mg, which is indicated for the medical termination of M I F E P R E X™ (Mifepristone) Tablets, 200 mg PRESCRIBER’S AGREEMENT We are pleased that you wish to become a provider of Mifeprex* (Mifepristone) Tablets, 200 mg, which is indicated for the medical termination of](https://www.pdfsearch.io/img/7f4e703159bfb03b46fa119630a2ff85.jpg) | Add to Reading ListSource URL: www.fda.govLanguage: English |
---|
150![M I F E P R E X™ (Mifepristone) Tablets, 200 mg PRESCRIBER’S AGREEMENT We are pleased that you wish to become a provider of Mifeprex* (Mifepristone) Tablets, 200 mg, which is indicated for the medical termination of M I F E P R E X™ (Mifepristone) Tablets, 200 mg PRESCRIBER’S AGREEMENT We are pleased that you wish to become a provider of Mifeprex* (Mifepristone) Tablets, 200 mg, which is indicated for the medical termination of](https://www.pdfsearch.io/img/c427eaa6b72d08d33c4cadeef66a2fc0.jpg) | Add to Reading ListSource URL: www.fda.govLanguage: English |
---|